Determination of vital status at the end of the DIG trial

Controlled Clinical Trials

Volumn 24, Issue 6, 2003, Pages 726-730

  Collins, Joseph F ^a,b,c   Howell, Cindy L ^a   Horney, R Anne ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c VAMHCS   (United States)

Author keywords

Determination of vital status; Digoxin; Heart failure; Randomized clinical trials; Study closeout

Indexed keywords

DIGOXIN;

ARTICLE; CANADA; CLINICAL RESEARCH; CLINICAL TRIAL; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; METHODOLOGY; OUTCOMES RESEARCH; PATIENT INFORMATION; SINUS RHYTHM; UNITED STATES;

EID: 0344687462     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(03)00135-1     Document Type: Article

References (3)

1. The Digitalis Investigation Group. Rationale, design, implementation, and baseline characteristics of participants in the DIG trial: a large simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials. 17:1996;77-97.
2. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
3. U.S. Department of Health and Human Services, Office for Civil Rights. Standards for Privacy of Individually Identifiable Health Information (45 CRF Parts 160 and 164): Regulation Text. October, 2002.